| Literature DB >> 35954498 |
Shoichiro Ishizuki1, Yoshiyuki Nakamura1.
Abstract
Despite the significant progress made in the past several years in pharmacotherapies for skin cancer, such as BRAF/MEK inhibitors, immune checkpoint inhibitors, and Hedgehog pathway inhibitors, surgical removal of primary skin cancer is still the first choice of treatment unless distant metastases are evident. In cases of lymph node metastases with clinically palpable lymphadenopathy, lymph node dissection (LND) is typically performed for most skin cancers. In the surgical treatment of primary skin tumors, the surgical margin is critical not only for reducing the possibility of tumor recurrence but also for minimizing the cosmetic and functional complications associated with wide local excision. In contrast, dermatologic surgery can cause various complications. Although skin graft is frequently used for reconstruction of the surgical defect, extensive graft necrosis may develop if optimal stabilization of the graft is not obtained. LND also sometimes causes complications such as intraoperative or postoperative bleeding and postoperative lymphoceles. Moreover, as in other types of surgery, surgical site infection, intraoperative anxiety, and intraoperative and postoperative pain may also develop. These complications are frequently associated with significant morbidity and discomfort. In this review, we summarize the evidence from previous clinical studies regarding the optimal surgical margin for skin cancer and the methods for diminishing the complications associated with dermatologic surgery.Entities:
Keywords: lymph node dissection; skin cancer; skin graft; surgical margin
Year: 2022 PMID: 35954498 PMCID: PMC9367341 DOI: 10.3390/cancers14153835
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Previous randomized controlled trials to evaluate peripheral surgical margins for melanoma.
| Year | Researchers | Number | Thickness, | Location | Peripheral | Recurrence | OS Rate and/or MSS Rate | Follow-Up Period |
|---|---|---|---|---|---|---|---|---|
| 1991 | Veronesi et al. [ | 612 | ≤2 | Except lesions of face, finger or toes | 1 vs. 3 | 8 year-RFS rate: 81.6% in the 1 cm margin vs. 84.4% in the 3 cm margin ( | 8 year-OS rate: 89.6% in the 1 cm margin vs. 90.3% in the 3 cm margin ( | Mean, 91 months in 1 cm margin and 90 months in the 3 cm margin |
| 2001 | Balch et al. [ | 468 | 1–4 | Head/neck or extremity or trunk | 2 vs. 4 | LRR: 2.1% in the 2 cm margin vs. 2.6% in the 4 cm margin (no significant difference) | 10 year-MSS rate: 70% in the 2 cm margin vs. 77% in the 4 cm margin ( | Median, 10 years |
| 2003 | Khayat et al. [ | 326 | ≤2 | Except ALM | 2 vs. 5 | LRR: 0.6% in 2 cm margin vs. 2.4% in the 5 cm margin (no significant difference) | 10 year-OS rate: 87% in 2 cm margin vs. 86% in the 5 cm margin ( | Median, 16 years |
| 2012 | Hudson et al. [ | 576 | 1–2 | Whole body | 1 vs. 2 | LRR: 3.6% in 1 cm margin vs. 0.9% in the 2 cm margin ( | OS rate was not significantly different ** | Median, 38 months |
| 2004 | Thomas et al. [ | 900 | >2 | Trunk or limbs | 1 vs. 3 | Locoregional recurrence * rate up to 3 years was significantly higher in the 1 cm margin ( | OS rate was not significantly different ( | Median, 5.7 years |
| 2011 | Gillgren et al. [ | 936 | >2 | Trunk or upper or lower extremities | 2 vs. 4 | LRR: 4.3% in 2 cm margin vs. 1.9% in the 4 cm margin ( | Neither OS rate nor MSS rate was significantly different ( | Median, 6.7 years for analyses of LRR |
LRR: local recurrence rate; RFS: relapse-free survival; OS: overall survival; MSS: melanoma-specific survival; ALM: acral lentiginous melanoma. RFS rate is defined as the rate of subjects who do not show any disease recurrence. OS rate is defined as the rate of subjects who have not died by any causes. MSS rate is defined as the rate of subjects who have not died from melanoma. * Locoregional recurrence includes local recurrence, in transit metastasis and regional lymph node metastasis. ** There were 14 deaths (6.2%) in the 1 cm group and 33 deaths (9.4%) in the 2 cm group. *** Overall, 253 deaths (55.8%) occurred in 453 patients in the 1 cm group and 241 (53.9%) occurred in 447 patients in the 3 cm group (p = 0.14). In total, 194 deaths (42.8%) were attributed to melanoma in the 1 cm group, as compared with 165 (36.4%) in the 3 cm group (p = 0.041). **** There were 304 deaths (49%) in the 2 cm group and 317 deaths (51%) in the 4 cm group (p = 0.75). In total, 192 deaths (48%) were attributed to melanoma in the 2 cm group, as compared with 205 (52%) in the 4 cm group (p = 0.61).
Comparison of guideline-suggested peripheral margin in melanoma [16].
| Organization | Peripheral Margin | |||||
|---|---|---|---|---|---|---|
| Tumor Thickness (Breslow) in Melanoma | In Situ | <1 mm | 1–2 mm | 2.01–4 mm | 4 mm< | |
| NCCN | 0.5–1 cm | 1 cm | 1–2 cm | 2 cm | ||
| AAD | 0.5–1 cm | 1 cm | 1–2 cm | 2 cm | ||
| ESMO | 0.5 cm | 1 cm | 2 cm | |||
| CCA | 1.01–2 cm | 2 cm | ||||
NCCN: National Comprehensive Cancer Network. AAD: American Association of Dermatology. ESMO: European Society of Medical Oncology. CCA: Cancer Council Australia.
Previous representative studies to evaluate the effect of MMS and recommendations of the current NCCN guidelines for MMS for each skin cancer.
| Type of Cancer | Year | Researchers | Type of Study | Number | Limitation of Location or Stage | LRR | Prognosis (Survival or Development of Metastases) | Follow-Up Period | Recommendation of NCCN Guidelines |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | 1997 | Zitelli et al. [ | Retrospective study | MMS, 369 | None | MMS, 0.5%; historical WLE, 3% | 5-year OS rate: 93% | 5 years except for 3 patients | The NCCN guidelines do not recommend MMS for primary treatment of invasive cutaneous melanoma when standard clinical margins can be obtained [ |
| 2016 | Valentin-Nogueras et al. [ | Retrospective study | MMS, 2114 | None | MMS, 0.49%; historical WLE, 9–20% | 5-year disease-specific survival rate: 98.5% | Mean, 3.73 years | ||
| 2019 | Hanson et al. [ | Retrospective study | MMS, 46,887; WLE, 3510 | Head and neck | NA | A better OS in MMS than in WLE (WLE HR, 1.181; 95% CI, 1.08–1.29; | NA | ||
| 2019 | Cheraghlou et al. [ | Retrospective study | MMS, 3234; WLE, 67,085 | Stage I * | NA | A better OS in MMS than in WLE (HR, 1.16; 95% CI, 1.03–1.32) | Mean, 4.81 years | ||
| 2020 | Demer et al. [ | Retrospective study | MMS, 4413; WLE, 184,449 | Trunk and extremities | NA | No significant difference in OS (WLE HR, 1.03; 95% CI, 0.94–1.13; | NA | ||
| SCC | 2005 | Leibovitch et al. [ | Prospective observational study | 381 | None | Primary SCC, 2.6%; recurrent SCC, 5.9% | No cases with metastases during the follow-up period | 5 years | The NCCN guidelines recommend MMS as the preferred surgical technique for high-risk SCC [ |
| 2010 | Pugliano-Mauro et al. [ | Retrospective study | 260 | None | 1.2% | Six tumors (2.3%) metastasized. | A minimum of 2 years | ||
| 2019 | Xiong et al. [ | Retrospective study | MMS, 240; WLE, 126 | T2a ** | MMS, 1.2%; WLE, 4.0% ( | A significantly lower cumulative incidence of overall disease progression *** in MMS than in WLE (WLE HR, 2.9; 95% CI, 1.1–7.6; | Mean, 2.8 years | ||
| BCC | 2008 | Mosterd et al. [ | Prospective randomized controlled study | MMS, 198; WLE, 199 in primary BCC; MMS, 100; WLE, 102 in recurrent BCC | Face | MMS, 4.4%; WLE, 12.2% in primary BCC ( | NA | Median, 79.2 months in primary BCC and 85.0 months in recurrent BCC | The current NCCN guidelines recommend MMS as a preferred technique for the treatment of high-risk BCC [ |
| MCC | 2022 | Carrasquillo et al. [ | Systematic literature search | MMS, 58; WLE, 4216 | Stage I * | MMS, 8.5%; WLE, 6.8% ( | No significant difference in regional and distant metastases between MMS and WLE | NA | The NCCN guidelines recommend MMS as an alternative method when it does not interfere with sentinel lymph node biopsy [ |
| EMPD | 2004 | Hendi et al. [ | Retrospective study | 27 | None | MMS, 26%; historical WLE, 33–60% | Two patients developed metastases | Mean, 58.6 months; median, 55.5 months | NA |
| DFSP | 2008 | Paradisi et al. [ | Retrospective study | MMS, 41; WLE, 38 | None | MMS, 0%; WLE, 13.2% ( | No cases with metastases during the follow-up period | Mean, 5.4 years in MMS and 4.8 years in WLE | The NCCN guidelines recommend MMS rather than WLE if MMS is available [ |
| 2021 | Gonzalez et al. [ | Retrospective study | 41 | Head and neck | MMS, 2.4%; historical WLE, 9–73% | No cases with metastases during the follow-up period | Mean, 92.6 months | ||
| 2022 | Serra-Guillen et al. [ | Retrospective study | 222 | None | 0.9% | NA | Mean, 71.5 months; | ||
| AFX | 2021 | Jibbe et al. [ | Systematic literature search | MMS, 71; WLE, 30 | None | 8.3% (MMS) vs. 26.7% (WLE) | NA. | Mean, 41.4 months | NA |
MMS: Mohs micrographic surgery; NCCN: National Comprehensive Cancer Network; LRR: local recurrence rate; OS: overall survival; WLE: wide local excision; NA: not applicable; HR: hazard ratio; CI: confidence interval; SCC: squamous cell carcinoma; BCC: basal cell carcinoma; MCC: Merkel cell carcinoma; EMPD: extramammary Paget disease; DFSP: dermatofibrosarcoma protuberans; AFX: atypical fibroxanthoma. * Stage-I tumors were classified according to the American Joint Committee on Cancer Staging Manual, 8th edition. ** T2a tumors were defined as having 1, but not multiple, high-risk features (tumor diameter ≥2 cm, poorly differentiated histology, perineural invasion ≥0.1 mm, and tumor invasion beyond fat). *** Disease progression was defined as either overall recurrence or tumor-specific death.